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The development of highly effective and durable vaccines against the human malaria parasites Plasmodium
falciparum and P. vivax remains a key priority. Decades of endeavor have taught that achieving this goal will
be challenging; however, recent innovation in malaria vaccine research and a diverse pipeline of novel vac-
cine candidates for clinical assessment provides optimism. With first-generation pre-erythrocytic vaccines
aiming for licensure in the coming years, it is important to reflect on how next-generation approaches can
improve on their success. Here we review the latest vaccine approaches that seek to prevent malaria infec-
tion, disease, and transmission and highlight some of the major underlying immunological and molecular
mechanisms of protection. The synthesis of rational antigen selection, immunogen design, and immunization
strategies to induce quantitatively and qualitatively improved immune effector mechanisms offers promise
for achieving sustained high-level protection.Introduction
Modern malaria vaccine development began with seminal
studies in mice using irradiated sporozoites (Nussenzweig
et al., 1967). Although there is still no licensed product over
50 years later, it is important to remember the scale of the scien-
tific and technical challenges facing those who develop vaccines
against such a complex eukaryotic parasite. Moreover, steady
progress is being made, especially with regard to breakthroughs
in our understanding of the cellular and molecular mechanisms
mediating protection in animal models and humans. The revised
Malaria Vaccine Technology Roadmap to 2030 (Moorthy et al.,
2013) now calls for a next-generation vaccine to achieve 75% ef-
ficacy over 2 years against P. falciparum and/or P. vivax (in an era
of renewed global interest toward malaria elimination and erad-
ication), while also retaining its original 2015 ‘‘landmark’’ goal of a
first-generation vaccine with protective efficacy of >50% lasting
more than 1 year. Achieving this next-generation vaccine goal
will necessitate building on the success of current pre-erythro-
cytic subunit and whole sporozoite-based vaccines, as well as
new strategies to add blood-stage or transmission-blocking
immunity. Here we review the progress and prospects for a
diverse range of approaches targeting different stages of the
P. falciparum parasite’s complex life cycle (Figure 1), before
discussing those in development for P. vivax.
Sporozoite Subunit Vaccines
The most extensively tested vaccine candidate for prevention
of P. falciparum malaria is RTS,S/AS01; this vaccine directs im-
mune responses against the major circumsporozoite protein
(PfCSP) covering the surface of the infecting sporozoite. To
accomplish this, RTS,S was designed as a virus-like particle
(VLP) comprised of two components: 18 copies of the centralCell Host & Microbe 24
This is an open access article undrepeat and the C-terminal domain of PfCSP fused to hepatitis
B virus surface antigen (HBsAg) with extra HBsAg in a 1:4 ratio.
RTS,S, formulated with the potent liposomal adjuvant system
AS01 fromGlaxoSmithKline, is the only vaccine that has demon-
strated protective efficacy against clinical malaria in a Phase III
clinical trial (Rts, 2015), although protection is partial, wanes
over time, and may be age dependent (protection was lower in
infants 6–12 weeks of age than in young children 5–17 months
old). In the latter, receiving three vaccinations in a 0-1-2 month
schedule, the incidence of clinical malaria was reduced by
51% over the first year of follow-up post-dose three [95% CI
48%–55%]. Over 48 months of follow-up, efficacy was 26%
[95% CI 21%–31%], and among children receiving a fourth
dose at month 20 (18 months post-dose three), efficacy was
39% [95%CI 34%–43%]. A small Phase II study, which followed
several hundred children who received the three-dose regimen
over 7 years, suggests that there may also be a shifting or
rebound in malaria incidence 5 years post-vaccination (Olotu
et al., 2016). Results of a larger long-term follow-up study to
the Phase III efficacy and safety trial are expected later this
year. According to the World Health Organization (WHO), two
safety signals (meningitis, cerebral malaria) emerged from the
Phase III trial, for which the cause is unknown and they noted a
confirmed risk of febrile convulsions within 7 days of vaccination
in the 5–17 month age category, all of which resolved without
long-term sequelae (WHO, 2016). Following a positive opinion
from European regulatory authorities in July 2015, WHO recom-
mended large-scale pilot implementations to further evaluate the
feasibility of delivering four doses, the vaccine’s potential for
reducing childhood deaths, and to provide additional data on
safety in the context of routine use. The pilot implementation pro-
gram will include robust safety surveillance of these and other, July 11, 2018 ª 2018 The Author(s). Published by Elsevier Inc. 43
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Figure 1. Malaria Vaccine Candidates in Clinical Development
Data sources for this figure included the WHO Malaria Vaccine Rainbow Table and Clinicaltrials.gov. Vaccines for P. vivax are colored blue. The life cycle figure
was adapted from Nilsson et al. (2015).
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assessed in the Phase III trial due to very low mortality in the trial
overall.
One of the most important imperatives for future improve-
ments to RTS,S/AS01, and all next-generation malaria vaccines,
is to extend the period of protection, which will require further
understanding the mechanisms of vaccine-induced efficacy.
While a definitive immune mechanism remains to be determined
for RTS,S/AS01, the existing data strongly suggest that high
antibody concentrations against the NANP amino acid repeats
are closely associated with protection, and waning of such re-
sponses is likely to be responsible for decreasing efficacy (White
et al., 2015). A direct mechanistic link between a monoclonal
antibody (mAb) against the NANP epitope (isolated from a sub-
ject immunized with RTS,S [Oyen et al., 2017]) and protection
will be tested soon following passive transfer and controlled
human malaria infection (CHMI) (Figure 2). RTS,S also contains
the C-terminal region of PfCSP; however, the role of antibody re-
sponses to this region remains unclear as a recent study showed
that a number of such mAbs, obtained from a human subject
immunized with sporozoites, are not protective in a mouse
model (Scally et al., 2018). In addition to antibody, CD4+ T cell re-
sponses have been suggested to have some role in protection
(Kazmin et al., 2017). In some support of this, the C terminus of44 Cell Host & Microbe 24, July 11, 2018PfCSP, present in RTS,S, contains two well-defined CD4+
T cell epitopes, and a genetic analysis of the Phase III trial indi-
cates a significant sieving effect with modestly lower efficacy
for C-terminal sequence unmatched strains (Neafsey et al.,
2015). However, a definitive immune mechanism for this effect
remains to be determined, and for now the major limitation of
RTS,S appears to be maintaining the high antibody levels.
It therefore seems critical for future PfCSP-based subunit vac-
cines to take into account the parameters of vaccine-induced
antibody concentration decay. RTS,S is administered with the
adjuvant AS01—the leading formulation for induction of high
antibody concentrations in humans. Peak polyclonal anti-
NANP serum IgG responses after the final immunization aver-
aged 150 mg/mL in malaria-naive adults (Kester et al., 2009),
and in the Phase III trial antibody levels declined sharply with
initial half-life of 40 days followed by a period of slower decline
of 600 days (White et al., 2015). The requirement for such high
and sustained antibody concentrations to mediate durable
protection poses a substantial challenge. The impact of novel
adjuvants and vaccine delivery platforms may help to provide a
solution in the future, especially if they can be demonstrated to
skew immune responses toward improved induction of long-
lived plasma cells. Antibody decay parameters for an HIV enve-
lope protein delivered with eight different clinical adjuvants have
Figure 2. CHMI Models for Vaccine Efficacy
Testing
Blood-stage parasitemia is monitored by qPCR
with lower limit of quantification 20 parasites/mL
blood (black dotted line), typically for a 21 day
study period. Malaria-naı̈ve volunteers are usually
diagnosed and treated at 10,000 parasites/mL
when patent by thick-film microscopy (black
dashed line). Following sporozoite CHMI, sterile
protection is measured or a partial vaccine effect
can be assessed by analysis of the liver-to-blood
inoculum (LBI) leading to a delay in time to diag-
nosis. For blood-stage CHMI, an inoculum of
1,000 parasites is administered IV on day 0, with
parasites growing 10-fold per 48 hr (red line)
(Payne et al., 2016). For an effective blood-stage
vaccine, a reduction in the parasite multiplica-
tion rate (PMR) would be expected. To assess
transmission, CHMI is initiated by sporozoites or
blood-stage inoculum (the figure depicts the latter).
A low-dose drug regimen is used to treat asexual
parasitemia, followed by a curative regimen if
recrudescence occurs. A wave of gametocytemia
then ensues, with all volunteers receiving drug
treatment to clear parasites at the end of the study
period (Collins et al., 2018).
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2017), and the data demonstrate some differences in how adju-
vants can influence durability. Nevertheless, improving upon the
magnitude of antibody responses by adjuvants other than AS01
may be difficult to achieve. Consequently, an alternative strategy
to achieve sustained protection with lower antibody concentra-
tions is by improving the potency or breadth of the polyclonal
antibody (pAb) response. The induction of pAb functional at
lower concentrations should result in improved vaccine efficacy
during a longer segment of the IgG decay curve. Altered vaccine
regimens or identification of new neutralizing epitopes on PfCSP
could guide such an approach, given that RTS,S does not
contain the N-terminal region and portions of the repeat region.
Similarly, a more detailed understanding of the contribution
made by antibody Fc-mediated effector functions as well as
binding parameters, such as affinity, to sporozoite blockade
will be important when seeking to design vaccines that induce
optimal pAb potency.
Interestingly, the most recent advance in RTS,S/AS01 vaccine
development has beenmade through amodification of dose and
schedule: 10/16 (62%) volunteers given the full dose at the stan-
dard 0-1-2month regimenwere protected against CHMI 3weeks
after the last immunization; in contrast, 26/30 (86%) volunteers
were protected when the third vaccine administration occurred
6 months after the second with the dose reduced to one-fifth
of the original dose (‘‘fractional dose,’’ Fx). Immunological anal-
ysis to determine the mechanism for these findings showed that
the titers of anti-NANP antibody were similar between the two
groups but the Fx regimen may affect antibody avidity, somatic
hypermutation, and isotype switching (Regules et al., 2016).
While it remains unclear whether the prolonged interval and/or
the reduced dose of the final vaccine aremediating these effects,
the data raise interesting questions about how this simple alter-
ation controls antibody quality. However, it is important to note
that while short-term protection was strikingly improved withthe Fx regimen, only 3/7 subjects were protected following sec-
ondary CHMI 8 months later. These data suggest that durability
of protection will need to be further assessed in future clinical
trials and likely improved and, importantly, it remains to be deter-
mined whether this altered schedule will lead to improved pro-
tection in the field.
Important new information will also emerge from clinical
testing of next-generation vaccine designs. The R21 vaccine is
composed of a single subunit (equivalent to ‘‘RTS’’ alone without
the 4-fold excess HBsAg) (Collins et al., 2017). The display of
a higher proportion of PfCSP and less HBsAg per VLP may
lead to improved anti-NANP IgG responses in comparison to
RTS,S. Clinical testing is underway using Matrix-M or AS01 ad-
juvants. In an alternative approach, full-length PfCSP containing
the N-terminal non-repeat region has been manufactured for
clinical testing (Genito et al., 2017), providing the potential to
induce antibodies against additional epitopes (not present in
RTS,S) that show anti-parasitic function in mice (Espinosa
et al., 2015).
A major new approach to the field of vaccine research
and development for viral proteins such as HIV, influenza, and
RSV has been structure-based vaccine design (Kwong, 2017).
A starting point is the isolation of a mAb from humans exposed
to a given infection or by a vaccine that shows potent neutralizing
function. The structure of the epitope bound by themAb is deter-
mined at atomic resolution and this information is used to design
immunogens with the goal of eliciting antibodies with functional
activity. Structure-guided vaccine design is just beginning for
malaria target antigens, including PfCSP (Figure 3). A detailed
molecular picture of protein conformations within the full-length
PfCSP as well as the binding characteristics of anti-NANPmAbs,
derived from RTS,S vaccinees, are providing blueprints for
advanced vaccine designs (Oyen et al., 2017). A novel subclass
of highly potent anti-PfCSP antibodies, which bind a unique and
conserved site of vulnerability found at the junction between theCell Host & Microbe 24, July 11, 2018 45
Figure 3. A Structure-Guided Approach to
Malaria Vaccine Development
Structuresof essentialPlasmodiumsurfaceproteins
in complexwith Fab fragments frommAbsprovide a
potential starting point for structure-guided vaccine
development. Inhibitory mouse mAbs (9AD4 and
QA1) binding on PfRH5 are shown (Wright et al.,
2014). A mouse binding-inhibitory antibody (2D10),
which can prevent PvDBP_RII from binding to hu-
man erythrocytes, has been shown to bind to the tip
of its third subdomain (Chen et al., 2016). Antibodies
that bind the NANP repeats of PfCSP prevent he-
patocyte invasionby sporozoites (Oyenet al., 2017).
Structural studies have also revealed Pfs25 bound
to six different mouse mAbs, identifying two trans-
mission-blocking epitopes, illustrated by the com-
plexes with 1190 (epitope I) and 1260 (epitope II)
(Scally et al., 2017).
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reported. These ‘‘junctional-binding’’ mAbs appear to be supe-
rior to comparator anti-NANP antibodies for protection in vivo
as assessed against P. falciparum infection in humanized liver-
chimeric mice (Kisalu et al., 2018; Tan et al., 2018). Given that
RTS,S contains NANP repeats but lacks the full junctional
epitope, it will be interesting to see whether these emerging
structure-function data can now be harnessed for superior
immunogen design leading to more potent anti-PfCSP pAb re-
sponses.
Equally important is the identification of non-PfCSP sporozoite
vaccine antigens. The only other target to enter recent clinical
testing is recombinant PfCelTOS, a micronemal secreted-pro-
tein (Draper et al., 2015), but no efficacy against CHMI was
observed when formulating in GLA-SE adjuvant, although overall
immunogenicity was modest. Preclinically, extensive lists of po-
tential antigens have been reported using genomic, proteomic,
and transcriptomic-based approaches (Swearingen et al.,
2016) alongside immuno-screening of human samples from
naturally exposed or experimentally immunized individuals (Da-
vies et al., 2015). However, prioritization of these targets requires
an anti-sporozoite screening assay that closely associates with
clinical protection. Defining such an assay remains a critical
challenge for the future.
Whole Sporozoite Vaccines
Various whole sporozoite vaccine (WSV) strategies have demon-
strated high levels of protection in preclinical animal models and
humans against homologous CHMI, with current studies aiming
to define efficacy in malaria-endemic populations, as well as the
breadth and duration of protection. WSV rely on administration
of live-attenuated sporozoites that cease development at
various stages prior to the fulminant blood-stage infection or
live sporozoites that reach the blood but are eliminated by drugs.
Preclinical studies in rodents show that the timing of arrest has
major implications for the breadth and potency of the immune
response.
Radiation-attenuated sporozoites (RAS), which were the first
WSV studied in both rodents and humans, arrest at random
points early in liver-stage development and were first shown to
confer protection in humans when administered by mosquito
bites. A major advance for vaccine development was the ability
to isolate a purified, aseptic, and cryopreserved product of46 Cell Host & Microbe 24, July 11, 2018RAS for clinical trials (‘‘PfSPZ Vaccine’’). A subsequent scientific
advance showed that intravenous (IV) administration of PfSPZ
Vaccine was required for inducing potent immunity in humans
(Seder et al., 2013) and was associated with robust tissue-resi-
dent PfSPZ-specific CD8+ T cell responses in the livers of NHP
as compared to subcutaneous immunization (Epstein et al.,
2011). Indeed, subcutaneous administration showed limited pro-
tection against CHMI. These studies provided the first evidence
for using IV administration of a preventive vaccine in humans.
More recent results with PfSPZ Vaccine from sub-Saharan Africa
have been mixed but encouraging. A trial in Malian adults re-
ported that PfSPZ Vaccine was well-tolerated, safe, and easy
to administer by direct venous inoculation (DVI) of healthy adults
in the clinical trial setting. The proportion of participants with any
infection from 28 days after the fifth vaccination to the end of the
malaria season (20 weeks) was lower in the vaccinated group
than in the control group (HR 0.71, 95% CI 0.53–0.92) (Sissoko
et al., 2017). These data suggest that WSV can provide some
protection against malaria infection during intense transmission
(93% infection rate among placebos). However, a direct com-
parison of the efficacy of this vaccine to other vaccines is limited
by differences in trial designs, efficacy endpoints, and statistical
approaches. Efficacy in Mali was also lower than following CHMI
of U.S. adults with either homologous or heterologous parasites
(Ishizuka et al., 2016; Lyke et al., 2017), although better than that
seen with heterologous (7G8 strain) CHMI at 24 weeks (Epstein
et al., 2017). Notably, both the trial in Mali and another recent trial
in Equatorial Guinea (Olotu et al., 2018) reported lower anti-
PfCSP IgG responses in contrast to the same vaccine regimen
in U.S. adults, which may reflect hypo-responsiveness to vacci-
nation in malaria-exposed adults; on-going studies will seek to
overcome this obstacle through dose and regimen optimization.
Moreover, further assessment of protection in young infants
in Africa is also required, which will also provide more data
on the deployability and feasibility of a vaccine requiring DVI
administration.
In contrast to RAS, targeted gene deletion of sporozoites
provides a means of homogeneous attenuation. The first clinical
trial using a P. falciparum genetically attenuated parasite (GAP),
lacking two genes p52/p36, led to a breakthrough infection
(Spring et al., 2013). However, more recent data showed
that a GAP vaccine lacking three genes (p52/p36/sap1;
‘‘PfGAP3KO’’) arrests early in liver-stage development and was
Cell Host & Microbe
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delivery in U.S. adults (Kublin et al., 2017). CHMI efficacy data for
this and another GAP called PfSPZ-GA1 (lacking two genes b9/
slarp) are awaited. Potentially more promising are the next gen-
eration of GAP vaccines. Such vaccines would arrest later in the
liver, which in rodent models engenders more antigenically
diverse immune responses (breadth of immunity) that are effica-
cious at lower doses and protect against the blood-stage and
multiple rodent parasite species (Sack et al., 2015). Making
such late-arresting GAPs in P. falciparum has proved chal-
lenging, but aP. falciparum version of a new rodent late-arresting
GAP (lacking the genes plasmei2 and lisp2) (Vaughan et al., 2018)
is under development.
A final WSV strategy delivers wild-type sporozoites under
chloroquine drug cover, thus allowing liver-stage parasites to
develop fully prior to being killed upon entry into the blood to pre-
vent clinical illness. This approach, initially called ‘‘chloroquine
prophylaxis with sporozoites’’ (CPS), was protective in 100%
of volunteers at 8 weeks after final immunization, with 4/6 volun-
teers still protected following CHMI 2 years later (Roestenberg
et al., 2011). However, this approach has recently shown limited
protection against heterologous CHMIwith two different parasite
strains (Walk et al., 2017). The mechanistic reason for this is un-
clear but may relate to strain-specific immunity of the vaccine or
inter-strain differences in liver infectivity that affect challenge po-
tency in CHMI compared to conventional homologous CHMI
with the NF54 strain. Use of a specific regimen with non-irradi-
ated, cryopreserved sporozoites delivered by DVI under chloro-
quine cover (PfSPZ-CVac) has recently shown 100% efficacy (in
9/9 volunteers) against homologous CHMI (Mordm€uller et al.,
2017), and notably the number of sporozoites required for immu-
nization is 10- to 100-fold less than using irradiated PfSPZ.
Assessment of this regimen against heterologous CHMI or natu-
ral exposure in field studies is underway. A clear challenge with
this approach will be overcoming the potential safety issues
related to using a live vaccine that requires concomitant drug
delivery to prevent disease; nevertheless, CPS remains an
extremely powerful approach to study highly effective malaria
immunity.
A major effort in all the aforementioned vaccine studies has
been to analyze innate and adaptive immunity to determine cor-
relates and mechanisms of protection. In this regard, our under-
standing of the roles of both antibodies and T cells in mediating
WSV-induced immunity has expanded rapidly in recent years. In
terms of IgG antibodies, since WSV vaccines contain the natural
sporozoite, they can induce a potentially broad range of anti-
genic specificities including those against PfCSP in its native
confirmation, although titers against the latter remain hard to
interpret without direct comparison to PfCSP-based subunit
vaccines. Nevertheless, serum from PfSPZ Vaccine-immunized
volunteers demonstrates functional in vitro, complement-fixing
anti-sporozoite IgM (Zenklusen et al., 2018), while passive trans-
fer of purified IgG from malaria-naive US subjects that received
the PfSPZ Vaccine and were protected can reduce liver infec-
tion >90% in humanized liver-chimeric mouse models (Ishizuka
et al., 2016). Of note, the in vivo functional inhibition was highest
from serum obtained immediately after the final immunization
and waned over one year. These data suggest that if antibodies
do play a role withWSV it would be soon after immunization, andlikely act in concert with T cells (as discussed below). Moreover,
these studies highlight thatWSV provide a platform for discovery
of novel antigens and effector mechanisms, and determining
whether these responses are dominated by IgG against PfCSP
or alternative targets will be of high future priority.
While recent focus has been on antibody responses, extensive
evidence reported in rodent models as well as NHP (Doll and
Harty, 2014) has shown cytotoxic CD8+ T cells as the major
effector mechanism responsible for sterile protection after
WSV immunization. Killing of an infected hepatocyte relies on an-
tigen-specific CD8+ T cells finding the handful of infected hepa-
tocytes—a situation complicated by the unique immunological
and architectural environment of the liver as well as the sheer
number of hepatocytes to patrol (>1011 hepatocytes/human
liver). Indeed, rodent studies have demonstrated that large
numbers of specialized liver-resident memory T cells (TRM) are
required to mediate killing of infected hepatocytes. These cells
rely on CXCR6 and CD69 to maintain long-term positioning in
the liver where they can patrol the sinusoids and respond rapidly
to infection (Fernandez-Ruiz et al., 2016; Tse et al., 2014).
Emerging data also suggest an important role for gd T cells in
the induction of such responses at the time ofWSV immunization
(Ishizuka et al., 2016; Zaidi et al., 2017). Unfortunately, although
accessible in NHPs, liver-resident cells aremissedwith sampling
of peripheral blood, likely explaining the modest efficacy of
peripherally administered WSV as well as why a clear peripheral
CD8+ T cell correlate of protection in WSV clinical trials has been
elusive.
Liver-Stage Subunit Vaccines
Generating strong CD8+ T cell responses against parasitized he-
patocytes with a subunit vaccine requires quite different immuni-
zation platforms. To-date, recombinant replication-deficient viral
vectored vaccines, especially a chimpanzee adenovirus sero-
type 63 (ChAd63) prime followed by a boost with modified
vaccinia virus Ankara (MVA), have emerged as the most
advanced strategy reaching Phase IIb field trials (Ewer et al.,
2015). The most widely tested vaccine insert in ChAd63-MVA
comprises the thrombospondin-related adhesion protein linked
to a multi-epitope string (ME-TRAP). Vaccination provides
20%–25% sterile protection against CHMI that associates
with a peripheral CD8+ T cell response (Ewer et al., 2013). The
same vaccine reduced the risk of infection in Kenyan adults by
67% (95%CI 33%–83%) over a short follow-up period (Ogwang
et al., 2015), but no efficacy was observed in Senegal (Mensah
et al., 2016). Efficacy assessment of this vaccine in the 5- to
17-month-old target age group remains on-going, with trials re-
porting more promising immunogenicity in contrast to African
adults (Bliss et al., 2017).
It also remains unclear whether ME-TRAP is the best choice of
antigen. CHMI studies with ChAd63-MVA vectors encoding
other well-characterized antigens (PfCSP, and the blood-stage
antigens PfMSP1 or PfAMA1) failed to improve on ME-TRAP
(Hodgson et al., 2015; Sheehy et al., 2012), while a DNA
prime–human adenovirus serotype 5 (AdHu5) boost regimen
using PfCSP and PfAMA1 achieved a comparable level of
sterile protection in 4/15 (27%) volunteers (Chuang et al.,
2013). Ideally, next-generation strategies would therefore seek
to identify antigens that provide better MHC class I presentationCell Host & Microbe 24, July 11, 2018 47
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T cell recognition and killing of infected hepatocytes (Huang
et al., 2015). Studies using WSV have suggested that sporozoite
surface proteins as well as liver-stage exported proteins can
be more efficiently presented and targeted than parasite-
cytoplasmic proteins (Doll et al., 2016; Montagna et al., 2014).
However, the potential list of antigens remains limited by an
incomplete knowledge of the proteins expressed during the
liver-stage of P. falciparum. The major limitation for both tran-
scriptomic profiling and identification by mass spectrometry of
peptide epitopes eluted from MHC molecules is a suitable and
sufficient source of infected hepatocytes. New developments
such as humanized liver-chimeric mouse models, in vitro liver-
stage culture methods, and sorting infected hepatocytes labeled
with brightly fluorescent P. falciparum lines will undoubtedly
expand the repertoire of liver-stage candidate antigens in the
coming years (Longley et al., 2015a). In the meantime, on-going
efforts continue to screen peripheral T cell responses for antigen
reactivity from immune volunteers immunized by WSV strate-
gies, although these are often hampered by lack of statistical
power and suitable reagents with which to measure weak re-
sponses to many hundreds of potential antigens. Moreover,
once identified, preclinical assays to prioritize antigens are chal-
lenging given that P. falciparum does not infect small animals,
and there is no robust in vitro assay to measure T cell-mediated
killing of liver-stage parasites. A recent alternative to emerge has
seen the use ofP. berghei rodentmalaria parasites transgenic for
P. falciparum liver-stage antigens of interest. Although an imper-
fect model, such studies have identified antigens that appear to
afford greater CD8+ T cell-mediated protection than PfTRAP
following immunization—including PfLSA1 and PfLSAP2 (Long-
ley et al., 2015b). A Phase I/IIa clinical trial of ChAdOx1-MVA
vectors encoding both these antigens in an insert called LS2 is
on-going.
Aside from antigen selection, recent evidence also suggests
that secondary antigen exposure in the tissue of interest is crit-
ical for engendering a TRM cell population. Thus, for liver-stage
subunit vaccines, a path forward may be so-called ‘‘prime-
target’’ strategies. In this scenario, T cell responses are primed
by peripheral vaccination, and then targeted by a boost with a
liver-directed vector, such as IV-delivered viral vector, which
serves to ‘‘target’’ and educate the T cells to remain in the liver.
These strategies have so far shown promise in mouse models
of malaria (Fernandez-Ruiz et al., 2016), with results of the
first Phase Ia trial to assess IV-delivered ChAd63 and MVA
ME-TRAP awaited.
Blood-Stage Vaccines
Naturally acquired immunity (NAI) to malaria arises through
repeated exposure to blood-stage parasite diversity, generation
of a broad antibody repertoire against merozoites and infected
erythrocytes, and a complex interplay of inflammatory and im-
muno-regulatory cellular responses. A chemically attenuated
whole-parasite blood-stage vaccine (Raja et al., 2017) and sub-
units against pregnancy-associated malaria using VAR2CSA
(Pehrson et al., 2017) have been recently developed that may
replicate aspects of NAI, with results awaited. Otherwise, exten-
sive efforts over recent decades have focused on a small handful
of well-studied merozoite antigens (usually dominant targets of48 Cell Host & Microbe 24, July 11, 2018NAI), seeking to induce antibodies that block erythrocyte inva-
sion; however, these have all struggled to achieve convincing
efficacy in clinical trials. Some have also challenged the merits
of this vaccine approach given that naturally immune individuals
with asymptomatic parasitemia contribute to malaria transmis-
sion. In this regard it is particularly encouragingly for the field
that new approaches are now emerging that target a small num-
ber of highly conserved merozoite antigens that do not appear
subject to significant natural immune evasion, challenging the
paradigm that blood-stage vaccine strategies should aim to
mimic NAI. The bar for such vaccines is high, necessitating
much stronger blockade of merozoite invasion than routinely
achieved by natural exposure. However, this ‘‘non-natural’’
form of malaria immunity could curtail blood-stage parasite
carriage, prevent disease, and development of gametocytes,
thereby aligning the goals to prevent both malaria disease and
transmission.
Given that this field has struggled, it is important to consider
the challenges that have faced vaccine candidates targeting im-
muno-dominant merozoite antigens. Most notably, these have
suffered from the induction of strain-specific pAb responses,
which cannot cover substantial levels of antigenic polymorphism
and/or redundant invasion pathways. Moreover, the kinetics of
merozoite invasion have important implications for all candidate
vaccines, and these have perhaps been under-appreciated in
the past. In vitro studies show that merozoites invade erythro-
cytes in <1 min (Weiss et al., 2016), with some antigens released
from organelles and only exposed for a fraction of this time.
These events are so rapid that extremely high concentrations
of antibody are required to overcome this constraint imposed
on antibody-antigen binding. Concentration (quantity) as well
as functional activity or ‘‘quality’’ (driven by target antigen
biology, epitopes recognized, antibody affinity, avidity, and sub-
class) will together determine the efficacy of vaccine-induced
pAb. Substantial improvements in both parameters are now
required for next-generation vaccines, if they are to achieve
high-level control of merozoite invasion and clearance in humans
(i.e., reduce multiplication per cycle to <1). On-going efforts to
address these challenges with the well-studied polymorphic
merozoite antigen PfAMA1 have focused on cocktails of alleles,
seeking antibodies against conserved epitopes and hence
breadth of parasite coverage (Sirima et al., 2017). However,
given that inhibition of homologous parasites is not enhanced,
an improved ‘‘quality’’ of the pAb is still required. In this regard,
one promising development has used vaccination with PfAMA1
in complex with its peptide ligand PfRON2, leading to improved
in vivo protection in Aotus monkeys (Srinivasan et al., 2017);
consistent with a qualitative shift in the pAb related to epitopes
recognized around the PfRON2 binding site.
More encouragement for this field, as discussed above, has
come from the recent identification of merozoite antigens that
appear to overcome the long-standing difficulties of polymor-
phism and redundancy—the most advanced of which is the
P. falciparum reticulocyte-binding protein homolog 5 (PfRH5),
which forms an essential interaction with basigin (CD147) on
the erythrocyte surface during invasion (Crosnier et al., 2011).
The high degree of PfRH5 sequence conservation is associated
with low-level natural immune pressure, coupled with functional
constraints linked to basigin binding and host erythrocyte
Figure 4. Functional Analysis of Human Antigen-Specific IgG
Reported EC50 [±95% CI] data from Phase Ia clinical trials of vaccine-induced
human antigen-specific IgG, as assessed for functional activity against blood-
stage (GIA) or sexual-stage parasites (SMFA). Vaccine-induced polyclonal IgG
responses are carefully quantified using affinity-purified ELISA standards
(Cheru et al., 2010; Miura et al., 2009) or calibration-free concentration analysis
(Hodgson et al., 2014).
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length PfRH5 induces pAb that inhibit in vitro all P. falciparum
lines tested to date, while Aotus monkeys are protected by
PfRH5 vaccination against a stringent heterologous challenge.
In this case, anti-PfRH5 serum IgG antibody concentration and
functional activity, measured using purified IgG in the standard-
ized cell-independent in vitro assay of growth inhibition activity
(GIA), were both associated with protective outcome (Douglas
et al., 2015). Two further NHP studies have identified the assay
of GIA as an in vitro correlate of vaccine-induced in vivo protec-
tion (Mahdi Abdel Hamid et al., 2011; Singh et al., 2006), with
passive transfer of a GIA-positive anti-PfRH5 human mAb also
showing in vivo protection in a humanized mouse model (Foquet
et al., 2018). These data suggest a threshold level of GIA is
required to protect and provide a benchmark to aim for in future
human clinical studies.
Careful quantification of vaccine-induced pAb responses has
now allowed for informative comparison between antigens using
this functional assay (Figure 4). Anti-PfRH5 antibodies appear to
block erythrocyte invasion to high efficiency, requiring lower an-
tigen-specific pAb concentrations to give 50% GIA (EC50) than
against PfMSP1 and PfAMA1—a consistent observation through
animal models and now vaccinated humans (Payne et al.,
2017b). Such quantitative analyses offer hope that highly sus-
ceptible antigen specificities can now be rationally identified to
overcome the challenge of merozoite invasion kinetics. Analysis
of anti-PfRH5 mouse mAbs also identified potent neutralizing
clones, with the best EC50 in the range of 10–15 mg/mL, although
room for improvement remains, given that this is 50-fold less
potent than anti-basigin mAbs where no kinetic constraint is
imposed on antibody binding (Zenonos et al., 2015). These
potent anti-PfRH5 clones bind within or extremely close to the
basigin binding site (Wright et al., 2014), suggesting future stra-
tegies for structure-guided immunogen design (Figure 3).
Furthermore, a multi-protein complex has now been eluci-
dated containing PfRH5 as well as PfRipr and PfCyRPA,
both of which are essential, highly conserved molecules that
elicit functional antibodies (Chen et al., 2011; Reddy et al.,
2015). This soluble PfRH5-PfRipr-PfCyRPA invasion complex
is required for triggering Ca2+ release and establishing the tight
junction (Volz et al., 2016), with the PfP113 surface proteinbinding the N terminus of PfRH5 to provide an anchor to the
merozoite surface (Galaway et al., 2017). Further complexities
surrounding PfRH5 biology have also been described, such as
interactions between cyclophilin B and basigin as well as
PfRhopH3 and PfRH5 (Prakash et al., 2017), or PfRAP2 and ba-
sigin (Zhang et al., 2018b). Importantly, targeting these multiple
components may improve vaccine potency; indeed antibodies
against PfRH5 and PfCyRPA can synergize (Reddy et al.,
2015), with recent structural analyses identifying inhibitory epi-
topes on PfCyRPA (Chen et al., 2017). Alternatively, targeting
discrete temporal steps during invasion may provide another
route to rational vaccine improvement. Indeed, a merozoite anti-
gen screen by reverse vaccinology identified targets that elicit
functional IgG, including PfRAMA whose antibodies synergized
with anti-PfRH5 and anti-PfCyRPA antibodies (Bustamante
et al., 2017). In parallel, other novel antigen combinations
continue to be identified by using protein libraries to screen Afri-
can sera (Morita et al., 2017), while further candidates are ex-
pected to arise from elegant experimental genetic approaches
(Zhang et al., 2018a). After many decades of difficulty, the mero-
zoite vaccine field is seeing a resurgence of candidates and
approaches, with the first human efficacy data of PfRH5-based
vaccines eagerly awaited.
Transmission-Blocking Vaccines
Unique among malaria vaccine strategies, those targeting the
sexual stages do not directly prevent infection or clinical symp-
toms within the host, but rather impact the parasite’s life cycle
in the mosquito vector aiming to prevent sporozoite develop-
ment and onward transmission. Proof-of-concept was first
reported in the 1970s, but substantial progress and political trac-
tion has only happened over the last decade, in line with renewed
calls for malaria elimination. Notably, while a transmission-
blocking vaccine (TBV) would not directly protect an individual,
it could have substantial impact: in an endemic population of
asymptomatic and/or submicroscopic carriers, a TBV will serve
to arrest onward transmission of malaria and thus provide
protection to the community as other vaccines do through
herd immunity.
The leading TBV antigens include the ookinete surface protein
Pfs25, and the gametocyte antigens Pfs48/45 and Pfs230. Anti-
bodies against all three perform well in comparative preclinical
studies (Kapulu et al., 2015), with functionality assessed by the
standard membrane feeding assay (SMFA) using mosquitoes
that are fed cultured gametocytes in the presence of whole
serum or purified IgG (notably efficacy of anti-Pfs230 antibodies
is also complement dependent). Identification of improved anti-
gen targets (based on proteomic and transcriptomic datasets
and protein microarray screens) remains an area of intense
research, with studies starting to yield promising results (Stone
et al., 2018). Other more recently identified targets of interest
include Pfs47, involved in parasite immune evasion in the
mosquito vector (Molina-Cruz et al., 2013), and PfHAP2, which
is expressed on the male gametocyte and microgamete and
is essential for membrane fusion during fertilization (Angrisano
et al., 2017).
Pfs25 was the first antigen to progress clinically; however, this
Phase Ia trial with Pfs25 protein formulated in Montanide ISA51
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platforms, such as conjugation to exoprotein A of Pseudomonas
aeruginosa (EPA) (Shimp et al., 2013) or fusion to IMX313, a pro-
tein heptamerization technology resulting in nanoparticle forma-
tion (Li et al., 2016). A number of candidates have now entered
clinical testing (Figure 1), with Pfs25-EPA/Alhydrogel the first
to be reported (Talaat et al., 2016). Here, anti-Pfs25 serum anti-
body levels correlated with activity in the SMFA (with 57 mg/mL
[95% CI 45–77 mg/mL] Pfs25-specific human IgG achieving
50% reduction in oocyst intensity), suggesting high-level trans-
mission blocking may require substantial antibody concentra-
tions (Figure 4). Indeed, defining whether a given level of SMFA
activity is sufficient to impact malaria transmission in the field re-
mains an intense area of research (Bompard et al., 2017; Miura
et al., 2016). Importantly, these studies have been enabled by
substantial progress with regard to standardizing the SMFA so
that TBV activity can be evaluated bymultiple laboratories (Miura
et al., 2013). Other labor-intensive studies are now seeking to
bridge to other assays used in the field, including the direct
membrane feeding assay (DMFA) using gametocytes isolated
from naturally infected individuals, direct skin-feeding assays,
as well as community-wide clinical endpoints (Brickley et al.,
2016). These efforts will lay the foundations for the interpretation
of field trial data. Indeed, extension of the Pfs25-EPA vaccine,
along with a second EPA-conjugated immunogen composed
of the small D1M domain of Pfs230 (MacDonald et al., 2016),
to field trials in Mali is now underway using both Alhydrogel
and the stronger adjuvant AS01 (Figure 1).
Other preclinical efforts continue to design a Pfs48/45 immu-
nogen that is suitable for clinical biomanufacture with promising
results reported for a chimeric antigen: this fuses a ‘‘correctly
folded’’ Pfs48/45 region containing the C-terminal 6-cysteine
(6C) domain (evaluated by recognition of the highly potent
conformation-dependent rat mAb45.1) to the R0 portion of the
asexual-stage PfGLURP. The chimera denoted R0.6C is pro-
duced in Lactococcus lactis and intended for clinical develop-
ment (Theisen et al., 2017). Other investigations designed to
seek the most potent epitopes on TBV targets have recently
identified two distinct immunogenic sites in crystal structures
of the Pfs25 antigen in complex with antibodies elicited by immu-
nization of human immunoglobulin loci transgenic mice (Scally
et al., 2017). These non-overlapping sites can be targeted simul-
taneously by antibodies to additively increase parasite inhibition,
providing a structural blueprint for next-generation immunogen
design (Figure 3). In parallel, work is also seeking to array
Pfs25 antigen on highly immunogenic VLP scaffolds. A recent
study compared chemical cross-linking to the Qb-bacterio-
phage, versus, and ‘‘plug-and-display’’ conjugation to the
AP205-bacteriophage using the SpyTag/SpyCatcher tech-
nology (Leneghan et al., 2017). While the chemically conjugated
VLP elicited the highest quantity of antibodies, the plug-and-
display VLP elicited the highest quality anti-Pfs25 antibodies
measured by SMFA. Extension of this work to two orthogonally
reactive split protein pairs is now enabling dual antigen immuni-
zation (Pfs25 and Pfs28) on a single synthetic nanoparticle
(Brune et al., 2017). These exciting developments in delivery
technologies for highly immunogenic arrayed antigens bode
well for the future testing of defined malaria antigen combina-
tions and improved immunogens.50 Cell Host & Microbe 24, July 11, 2018Vaccines for P. vivax
While most vaccine development has focused on the major
cause of malaria mortality, P. falciparum, an effective vaccine
could also greatly facilitate elimination of P. vivax in many areas
of the Americas and Asia-Pacific where standard malaria control
tools are facing unique challenges from this parasite’s biology
(Mueller et al., 2015). These include dormant hypnozoites in
the liver that cause relapsing infections in the absence of trans-
mission; early appearance of gametocytes before onset of
clinical symptoms; and a shorter development cycle in the
mosquito. As with P. falciparum vaccines used for elimination,
it is also likely that a P. vivax vaccine will be needed for the
entire population and not just infants, given that in many settings
transmission rates are relatively low and the population largely
non-immune.
An effective pre-erythrocytic vaccine could reduce primary
infections as well as prevent establishment of hypnozoites,
thus reducing the risk of multiple relapses contributing to trans-
mission (White et al., 2017). To-date, two subunit vaccines
targeting PvCSP have reached clinical trials, while no WSV
formulation has been developed and studies of PvRAS suggest
protection is only achieved in subjects who receive very high
doses (Arévalo-Herrera et al., 2016). In the case of PvCSP,
a soluble protein (VMP001/AS01) was immunogenic in U.S. vol-
unteers but failed to induce sterile protection following P. vivax
mosquito-bite CHMI; although a significant delay in time to
parasitemia was seen in 16/27 vaccinated subjects (Bennett
et al., 2016). A VLP similar to RTS,S/AS01, called CSV-S,S/
AS01 (Vanloubbeeck et al., 2013), was not progressed; although
a particle called Rv21 with a higher density of PvCSP on the VLP
surface is progressing to clinical development (Salman et al.,
2017). While progress with PvCSP has been slow, exciting tech-
nical developments including humanized liver-chimeric mice,
in vitro culture methods, and the P. cynomolgi monkey model
are now increasing access to hypnozoites, opening the door
for new vaccine candidates targeting these dormant forms
(Gural et al., 2018).
At the blood stage, P. vivax invasion is restricted to reticulo-
cytes that express the iron importer transferrin receptor 1
(TfR1/CD71) (Malleret et al., 2015) and requires the interaction
of the P. vivax Duffy-binding protein (PvDBP) with the human
Duffy antigen receptor for chemokines (DARC/Fy). Indeed, the
only two vivax vaccines in active clinical development (Figure 1)
both target the conserved, extracellular, cysteine-rich region II
(PvDBP_RII), with the first published data reporting promising
immunogenicity in a Phase Ia trial (Payne et al., 2017a); however,
detailed interrogation of vaccine-induced antibody responses
remains hampered by the lack of long-term in vitro culture
systems for this parasite. Preclinically, structural studies of
PvDBP_RII bound to its receptor and specific mouse mAbs
(Chen et al., 2016) are starting to identify important determinants
related to receptor-binding blockade and polymorphism-
mediated immune escape, thus guiding rational design of next-
generation PvDBP_RII immunogens (Chen et al., 2015) (Figure 3).
Notably, the PvDBP-DARC paradigm has also been challenged
with reports of P. vivax infection in Duffy-negative individuals
(Zimmerman et al., 2013) and a PvDBP gene duplication in
parasite isolates (Menard et al., 2013) likely representing a sec-
ond erythrocyte-binding protein (Hester et al., 2013), although
Figure 5. Examples of Approaches to Next-Generation Malaria Vaccine Discovery
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(Hostetler et al., 2016). Therefore, although the complete
molecular basis of P. vivax invasion into DARC-negative erythro-
cytes remains unknown, it may still involve PvDBP. In parallel
the complexity of other invasion ligand families, including the
reticulocyte-binding proteins (PvRBPs), is being described,
with PvRBP2b (a distant homolog of PfRH5—there is no clear
P. vivax ortholog of this high priority P. falciparum target) binding
TfR1 as a critical host factor defining P. vivax tropism for reticu-
locytes (Gruszczyk et al., 2018). These new candidates and
others from antigen arrays (França et al., 2017), as well as sug-
gestions that cytotoxic CD38+ CD8+ T cells may target parasites
residing withinMHC class I-expressing reticulocytes (Burel et al.,
2016), provide a growing wealth of targets and strategies on
which to build a next-generation blood-stage vaccine.
In the case of transmission blocking, the first TBV to ever enter
clinical development targeted P. vivax and not P. falciparum.
This Pvs25H/Alhydrogel protein vaccine elicited antibodies that
showed activity in DMFA, but vaccinations in a second trial
with Montanide ISA51 adjuvant were halted due to unexpected
reactogenicity (Wu et al., 2008). For now, new clinical TBV can-
didates for P. vivax remain awaited.
Outlook and Anticipated Future Developments
Over the next 5 years, it is possible that RTS,S/AS01will proceed
to application for licensure (although review and approval by na-
tional regulatory authorities is required for use in the pilot imple-
mentation expected to start in late 2018). If successful, this will
mark a major milestone in the malaria field. Other vaccines pur-
suing licensure include PfSPZ Vaccine and R21, although these
candidates require additional data. Next-generation vaccines
will be essential to follow in these footsteps if higher and sus-
tained levels of protection are to be achieved—either as new
or direct improvements to these pre-erythrocytic strategies
and/or to provide added blood-stage or transmission-blocking
immunity. Achieving this goal will necessitate new strategies,
many of which are already in preclinical development and
showing promise. These approaches fundamentally differ by
their need to induce functional antibodies against sporozoites,
merozoites, or sexual stages versus T cell-mediated immunity
against the infected hepatocyte; but a blueprint for these activ-
ities and key developments likely to be seen in the near future
for P. falciparum are outlined in Figure 5. It is likely that new clin-
ical vaccine candidates for P. vivax will follow based on similar
strategies and technologies, but these two major human
Plasmodium species are only distantly related and have very
different biology, so how fruitful this will be waits to be seen.
Alongside efforts to maximize life cycle stage-specific immu-
nity, combining clinical candidates in a multi-stage approach is
now an obvious option to address whether additive, or ideally
synergistic, protective efficacy can be achieved. Although a
recent trial of RTS,S/AS01 used in conjunction with the liver-
stage subunit ChAd63-MVA ME-TRAP did not show improved
protection against CHMI (Rampling et al., 2016), other preclinical
data suggest encouraging synergy when combining pre-erythro-
cytic and transmission-blocking vaccines (Sherrard-Smith et al.,
2018). The increasing number of candidate vaccines acting
around the parasite’s life cycle means that these and other
multi-stage strategies can now be explored clinically.52 Cell Host & Microbe 24, July 11, 2018Irrespective of life cycle stage, consistent themes and chal-
lenges currently pervade the P. falciparummalaria vaccine field.
For antibody-inducing strategies, these include the need for
more durable and/or functional responses to maintain vaccine
efficacy as induced IgG responses wane into thememory phase.
Responses will likely be improved through rational structure-
based immunogen design, optimized immunization regimens,
and VLP-based delivery platforms. For T cell-inducing strate-
gies, these need to deliver more durable and effective liver TRM
cells. Both approaches need to maintain focus on defining
immune mechanism-based correlates of protection to allow
identification of the best possible new target antigens and/or
combinations, while refining their immunogens to maximize vac-
cine breadth as well as quantitative and qualitative potency.
These considerations are paramount to avoid years of empirical
testing and disappointment, and instead, the wealth of recent
technological advances now at vaccine developers’ disposal
should allow for an informed and integrated approach to next-
generation vaccine design. Once coupled with on-going prog-
ress in terms of vaccine biomanufacture, human vaccine delivery
platforms and efficacy assessment by long-term and heterolo-
gous CHMI, the coming years promise to be an exciting time
that should engender hope that a highly effective vaccine may
be within reach.
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